Tempus AI, a pioneer in precision medicine and artificial intelligence, has announced the availability of its multimodal immune profile score (IPS) algorithmic test for research use only. This test aims to introduce advanced algorithmic diagnostics to immuno-oncology, marking the initial phase of Tempus' broader immunotherapy-based portfolio. Tempus is utilizing clinical, laboratory, genomic, and transcriptomic data in conjunction with Cleveland Clinic to identify patients who may benefit from immunotherapy. In order to designate results as IPS-Low or IPS-High, the IPS test, a pan-cancer, laboratory-developed test assesses immunotherapy-related biomarkers from DNA and RNA test results and generates a score ranging from 0-100. It is currently accessible to life sciences collaborators for research purposes and is anticipated to be made available to clinicians as an add-on option for Tempus xT and xR tests by the end of the year.
Tempus is conducting a study to evaluate the prognostic and predictive utility of IPS in advanced pan-cancer patients who are treated with immune checkpoint inhibitors, with results expected to be disclosed later. The company has acquired a machine-learning-based algorithmic test from Dr. Timothy A. Chan of Cleveland Clinic, designed to estimate the efficacy of immune checkpoint blockade by analyzing patient-specific factors. Tempus advanced precision medicine is advanced through its AI-enabled platform, which supports personalized patient treatment selection through its extensive multimodal data and AI-driven solutions.
